KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to -$22.4 million.

  • Halozyme Therapeutics' Cash from Financing Activities fell 220.69% to -$22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$571.1 million, marking a year-over-year decrease of 156.83%. This contributed to the annual value of -$218.9 million for FY2024, which is 46.36% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Cash from Financing Activities stood at -$22.4 million, which was up 92.51% from -$299.0 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Financing Activities ranged from a high of $367.8 million in Q2 2022 and a low of -$299.0 million during Q2 2025.
  • In the last 3 years, Halozyme Therapeutics' Cash from Financing Activities had a median value of -$3.3 million in 2025 and averaged -$86.5 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Cash from Financing Activities skyrocketed by 921.81% in 2022 and then plummeted by 26,480.45% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Cash from Financing Activities stood at -$156.0 million in 2021, then spiked by 104.06% to $6.3 million in 2022, then slumped by 4,048.81% to -$249.9 million in 2023, then grew by 1.40% to -$246.4 million in 2024, then tumbled by 220.69% to -$22.4 million in 2025.
  • Its Cash from Financing Activities was -$22.4 million in Q3 2025, compared to -$299.0 million in Q2 2025 and -$3.3 million in Q1 2025.